Headache News and Research

Latest Headache News and Research

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p < .001).

14 Dec 2008

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

Australians warned of rabies outbreak in Bali

The warning comes from the head of the Northern Territory's Centre for Disease Control, Dr. Peter Markey, who says anyone bitten or scratched on the island by an animal should seek medical advice; the warning also applies to people who have been to Bali recently.

14 Dec 2008

AstraZeneca responds to FDA advisory committees' recommendation on SYMBICORT

On December 11, 2008, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) - including the Drug Safety & Risk Management Advisory Committee, the Pediatric Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee - completed a review of the benefits and risks of asthma medications containing long-acting beta-agonists (LABAs).

12 Dec 2008

Merck Serono's Kuvan receives European marketing authorization

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission has granted marketing authorization for Kuvan(R) for the treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients.

10 Dec 2008

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.

8 Dec 2008

Alarm over high lead contamination of Esperance sea food

Alarm over high lead contamination of Esperance sea food. The presence of high concentrations of lead found in fish in a part of Western Australia has prompted a warning to people living in the Esperance area to avoid eating some local seafood.

8 Dec 2008

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

GlaxoSmithKline has announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of Promacta (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies.

7 Dec 2008

Natural killer T cells play important role in Lyme disease

A research team led by the La Jolla Institute for Allergy & Immunology and Albany Medical College has illuminated the important role of natural killer (NK) T cells in Lyme disease, demonstrating that the once little understood white blood cells are central to clearing the bacterial infection and reducing the intensity and duration of arthritis associated with Lyme disease.

3 Dec 2008

New sleeping pill could be the answer to jet lag

An experimental drug developed by Australian scientists could offer a new cure for jet lag and be a welcome alternative to addictive sedatives such as benzodiazepines.

3 Dec 2008

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

If cold symptoms persist it could be sinusitis

If your stuffy nose and headache last for more than two weeks, it may be more serious than a cold.

1 Dec 2008

Schoolies warned that after-effects of drinking or drug-taking could disguise the start of meningococcal disease

Following reports that an 18-year-old student celebrating 'schoolies' week on Queensland's Gold Coast has been hospitalised with meningococcal disease, health officials have warned schoolies that the after-effects of drinking or drug-taking could disguise the onset of the disease.

26 Nov 2008

Signs of stroke - most people ignorant

A Mayo Clinic study shows a majority of stroke patients don't think they're having a stroke -- and as a result -- delay seeking treatment until their condition worsens.

25 Nov 2008

Ustekinumab receives positive opinion in Europe for treatment of plaque psoriasis

Janssen-Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (CHMP).

24 Nov 2008

Nplate receives positive opinion for marketing authorisation in Europe

Amgen has announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate (romiplostim) in the European Union (EU).

21 Nov 2008

FDA approves tapentadol immediate-release tablets for pain in adults

Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option.

21 Nov 2008

FDA approves Banzel (rufinamide) for Lennox-Gastaut syndrome

The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome.

20 Nov 2008

Medications containing barbiturates or narcotics may make migraine worse

A team of researchers led by investigators at the Albert Einstein College of Medicine of Yeshiva University has determined that certain commonly-prescribed medications may have the unintended consequence of increasing the frequency of migraine attacks.

18 Nov 2008

Raptor Pharmaceuticals announces positive results for Convivia program

Raptor Pharmaceuticals Corp. has announced positive results in its Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.

11 Nov 2008